GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Cyclically Adjusted PB Ratio

Novo Nordisk A/S (Novo Nordisk A/S) Cyclically Adjusted PB Ratio : 66.41 (As of Apr. 27, 2024)


View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk A/S Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Novo Nordisk A/S's current share price is $126.85. Novo Nordisk A/S's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $1.91. Novo Nordisk A/S's Cyclically Adjusted PB Ratio for today is 66.41.

The historical rank and industry rank for Novo Nordisk A/S's Cyclically Adjusted PB Ratio or its related term are showing as below:

NVO' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 15.64   Med: 24.75   Max: 70.32
Current: 67.33

During the past years, Novo Nordisk A/S's highest Cyclically Adjusted PB Ratio was 70.32. The lowest was 15.64. And the median was 24.75.

NVO's Cyclically Adjusted PB Ratio is ranked worse than
99.38% of 641 companies
in the Biotechnology industry
Industry Median: 1.72 vs NVO: 67.33

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Novo Nordisk A/S's adjusted book value per share data for the three months ended in Dec. 2023 was $3.497. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.91 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novo Nordisk A/S Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Novo Nordisk A/S's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Cyclically Adjusted PB Ratio Chart

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.05 24.49 37.79 40.65 54.23

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.65 45.47 45.19 51.19 54.23

Competitive Comparison of Novo Nordisk A/S's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Novo Nordisk A/S's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Cyclically Adjusted PB Ratio falls into.



Novo Nordisk A/S Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Novo Nordisk A/S's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=126.85/1.91
=66.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk A/S's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Novo Nordisk A/S's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=3.497/116.7000*116.7000
=3.497

Current CPI (Dec. 2023) = 116.7000.

Novo Nordisk A/S Quarterly Data

Book Value per Share CPI Adj_Book
201403 1.131 99.600 1.325
201406 1.215 99.700 1.422
201409 1.240 99.700 1.451
201412 1.260 99.400 1.479
201503 0.879 100.200 1.024
201506 1.110 100.300 1.291
201509 1.248 100.200 1.454
201512 1.318 99.800 1.541
201603 1.070 100.200 1.246
201606 1.237 100.600 1.435
201609 1.221 100.200 1.422
201612 1.259 100.300 1.465
201703 1.136 101.200 1.310
201706 1.491 101.200 1.719
201709 1.532 101.800 1.756
201712 1.584 101.300 1.825
201803 1.506 101.700 1.728
201806 1.590 102.300 1.814
201809 1.543 102.400 1.758
201812 1.613 102.100 1.844
201903 1.500 102.900 1.701
201906 1.691 102.900 1.918
201909 1.652 102.900 1.874
201912 1.785 102.900 2.024
202003 1.715 103.300 1.937
202006 1.944 103.200 2.198
202009 2.028 103.500 2.287
202012 2.203 103.400 2.486
202103 2.029 104.300 2.270
202106 2.314 105.000 2.572
202109 2.285 105.800 2.520
202112 2.327 106.600 2.547
202203 2.167 109.900 2.301
202206 2.335 113.600 2.399
202209 2.258 116.400 2.264
202212 2.642 115.900 2.660
202303 2.554 117.300 2.541
202306 2.937 116.400 2.945
202309 2.976 117.400 2.958
202312 3.497 116.700 3.497

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novo Nordisk A/S  (NYSE:NVO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Novo Nordisk A/S Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry
Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.